Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lexaria Bioscience ( (LEXX) ) has provided an announcement.
Lexaria Bioscience Corp. announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference, where CEO Richard Christopher will present and engage in investor meetings. This participation underscores Lexaria’s commitment to advancing its market presence and engaging with stakeholders, potentially impacting its operations and industry positioning positively.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology. This platform enhances the oral delivery of drugs by improving bio-absorption, reducing side effects, and facilitating drug delivery across the blood-brain barrier. The company operates a licensed in-house research laboratory and holds a significant intellectual property portfolio with 50 patents granted worldwide.
Average Trading Volume: 168,376
Technical Sentiment Signal: Sell
Current Market Cap: $18.17M
For an in-depth examination of LEXX stock, go to TipRanks’ Overview page.